Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Precision Medicine Biotechnology Solutions Market - Strategic Insights and Forecasts, 2026-2031 | AI and Genomics Fuel 11.3% CAGR, Creating a $49.6 Billion Opportunity

globenewswire.com
PFE Pfizer is mentioned as a prominent participant investing in targeted therapies, genomic technologies, companion diagnostics, and advanced research capabilities within the growing precision medicine biotechnology solutions market. NVS Novartis is listed as a key player in the precision medicine biotechnology solutions market, investing in targeted therapies, genomic technologies, companion diagnostics, and advanced research. AZN AstraZeneca is named as a prominent company investing in targeted therapies, genomic technologies, companion diagnostics, and advanced research within the expanding precision medicine biotechnology solutions market. TMO Thermo Fisher Scientific is mentioned as a key participant investing in targeted therapies, genomic technologies, companion diagnostics, and advanced research within the precision medicine biotechnology solutions market. BMY Bristol-Myers Squibb is listed as a participant in the precision medicine biotechnology solutions market, investing in targeted therapies, genomic technologies, companion diagnostics, and advanced research. AMGN Amgen Inc. is identified as a participant in the precision medicine biotechnology solutions market, investing in targeted therapies, genomic technologies, companion diagnostics, and advanced research. ILMN Illumina, Inc. is mentioned as a participant in the precision medicine biotechnology solutions market, investing in targeted therapies, genomic technologies, companion diagnostics, and advanced research. QGEN QIAGEN N.V. is listed as a participant in the precision medicine biotechnology solutions market, investing in targeted therapies, genomic technologies, companion diagnostics, and advanced research.

Global Precision Medicine Biotechnology Solutions Market - Strategic Insights and Forecasts, 2026-2031 | AI and Genomics Fuel 11.3% CAGR, Creating a $49.6 Billion Opportunity Dublin, Oct. 05, 2026 (GLOBE NEWSWIRE) -- "Precision Medicine Biotechnology Solutions Market - Strategic Insights and Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The global precision medicine biotechnology solutions market is projected to increase from USD 29.1 billion in 2026 to USD 49.6 billion by 2031, representing a compound annual growth rate of 11.3%. Market expansion is supported by the increasing adoption of genomics, molecular diagnostics, biomarker testing, and advanced analytics in clinical decision-making.

Precision medicine biotechnology solutions are becoming central to healthcare strategies focused on individualized treatment, improved clinical outcomes, and reduced adverse effects. Growing applications in precision oncology, rare disease management, neurological disorders, cardiovascular conditions, and other chronic diseases are strengthening demand. Continued advances in sequencing technologies, bioinformatics, and patient data analysis are also supporting data-driven, patient-centric healthcare models.

Market Growth Drivers

The rising prevalence of cancer, cardiovascular disease, genetic disorders, and other complex conditions is a major factor driving market growth. Variations in patient response to conventional therapies have increased demand for treatments informed by genetic, molecular, and clinical characteristics. This approach supports more accurate therapy selection and improved treatment efficacy.

Technological progress in genomics is further accelerating adoption. Lower sequencing costs, faster processing, and broader availability of next-generation sequencing and whole genome analysis are expanding the use of genetic profiling in healthcare and pharmaceutical research. These technologies contribute to early disease detection, biomarker identification, targeted therapy development, and more efficient clinical research.

Artificial intelligence and big data analytics are also influencing the precision medicine biotechnology solutions market. AI-driven platforms can analyze extensive biological and clinical datasets to support predictive diagnostics, biomarker discovery, patient stratification, and personalized treatment planning. Pharmaceutical and biotechnology companies are using these capabilities to strengthen research and development pipelines and improve clinical trial design.

Market Challenges

High implementation costs remain a key market restraint. Genomic sequencing, specialized biomarker testing, advanced laboratory systems, and targeted therapies require significant investment. These costs can limit accessibility, particularly in developing markets and healthcare systems with restricted budgets.

Adoption is also affected by shortages of qualified professionals and limited laboratory infrastructure in some regions. Successful deployment requires expertise in genomics, molecular diagnostics, bioinformatics, and clinical data interpretation.

Data privacy, security, and regulatory compliance present additional challenges. Precision medicine programs rely on sensitive genetic and clinical information, increasing the need for secure data infrastructure, effective governance, and compliance with regional data protection requirements.

Technology and Application Insights

Genomic sequencing technologies, particularly next-generation sequencing, are expected to remain fundamental to market development. Their ability to identify genetic variations supports biomarker research, companion diagnostics, clinical decision-making, and targeted drug development. Bioinformatics platforms and integrated analytics tools are improving the scalability and clinical utility of these technologies.

Oncology represents the leading application segment, reflecting the high global cancer burden and the growing role of molecular profiling in therapy selection. Precision oncology increasingly incorporates companion diagnostics, liquid biopsies, genomic analysis, and biomarker testing to guide targeted treatment strategies. Additional growth opportunities are emerging across rare genetic disorders, neurological diseases, cardiovascular conditions, and chronic disease management.

Competitive and Strategic Outlook

The competitive landscape includes pharmaceutical, biotechnology, diagnostics, laboratory technology, and data analytics companies. Pfizer, Novartis, Roche, AstraZeneca, and Thermo Fisher Scientific are among the prominent participants investing in targeted therapies, genomic technologies, companion diagnostics, and advanced research capabilities.

Strategic collaborations between pharmaceutical and diagnostics companies are supporting the co-development of therapies and companion diagnostics. Market participants are also expanding genomic research programs, adopting AI-driven platforms, and strengthening data infrastructure. These initiatives are expected to accelerate commercialization, improve treatment selection, and increase the availability of precision medicine solutions across clinical settings.

Market Outlook

The precision medicine biotechnology solutions market is positioned for sustained long-term expansion as healthcare providers, researchers, and life sciences companies increase their use of molecular data and advanced analytics. Although cost, infrastructure, workforce, and data security challenges may influence adoption rates, continued innovation and broader clinical applications are expected to support market growth through 2031.

Key Benefits of the Report

Business Applications

Organizations use the report for industry analysis, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Key Topics Covered

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

3.4. Porter's Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations

3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PRECISION MEDICINE BIOTECHNOLOGY SOLUTIONS MARKET BY PRODUCT

5.1. Introduction

5.2. Sequencing Technologies

5.3. Bioinformatics & Data Analytics Platforms

5.4. Companion Diagnostics

5.5. Precision Therapeutics

5.6. Molecular Diagnostic Tools

5.7. Consumables & Reagents

5.8. Software & Digital Health Solutions

6. PRECISION MEDICINE BIOTECHNOLOGY SOLUTIONS MARKET BY TECHNOLOGY

6.1. Introduction

6.2. Genomics

6.3. Transcriptomics

6.4. Proteomics

6.5. Metabolomics

6.6. Epigenomics

6.7. Next-Generation Sequencing (NGS)

6.8. Polymerase Chain Reaction (PCR)

6.9. Artificial Intelligence & Machine Learning

7. PRECISION MEDICINE BIOTECHNOLOGY SOLUTIONS MARKET BY APPLICATION

7.1. Introduction

7.2. Oncology

7.3. Rare Genetic Disorders

7.4. Cardiovascular Diseases

7.5. Neurological Disorders

7.6. Infectious Diseases

7.7. Metabolic Disorders

7.8. Immunology & Autoimmune Diseases

8. PRECISION MEDICINE BIOTECHNOLOGY SOLUTIONS MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. India

8.6.3. Japan

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Pfizer Inc.

10.2. Novartis AG

10.3. F. Hoffmann-La Roche Ltd

10.4. AstraZeneca

10.5. Bristol-Myers Squibb

10.6. AbbVie Inc.

10.7. Amgen Inc.

10.8. Illumina, Inc.

10.9. QIAGEN N.V.

10.10. Thermo Fisher Scientific Inc.

10.11. Agilent Technologies, Inc.

11. APPENDIX

11.1. Currency

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key Benefits for the Stakeholders

11.5. Research Methodology

11.6. Abbreviations

For more information about this report visit https://www.researchandmarkets.com/r/qk96ip

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.